Q1 EPS Estimate for Esperion Therapeutics Lifted by Analyst

Key Points

• Zacks Research has raised its Q1 2026 earnings per share estimate for Esperion Therapeutics to ($0.15), an improvement from the previous estimate of ($0.16).
• The company reported a net loss of ($0.21) per share for its latest quarter, which was below analysts' consensus estimates, despite revenue of $65 million exceeding expectations.
• Esperion Therapeutics' stock is currently down 7.5%, and the company has a market capitalization of $291.35 million with an average price target of $7.00 among analysts.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research lifted their Q1 2026 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, July 28th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will earn ($0.15) per share for the quarter, up from their prior forecast of ($0.16). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' FY2026 earnings at ($0.22) EPS and Q1 2027 earnings at ($0.17) EPS.

Other equities analysts also recently issued reports about the stock. The Goldman Sachs Group reduced their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Esperion Therapeutics Trading Down 1.4%

Shares of Esperion Therapeutics stock traded down $0.02 during trading hours on Wednesday, reaching $1.40. 2,627,163 shares of the company's stock were exchanged, compared to its average volume of 5,082,185. The company has a 50 day moving average of $1.15 and a two-hundred day moving average of $1.33. Esperion Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $3.94. The stock has a market cap of $277.48 million, a P/E ratio of -1.75 and a beta of 0.82.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. The business had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ESPR. Nuveen LLC bought a new position in shares of Esperion Therapeutics during the first quarter worth approximately $4,446,000. Wasatch Advisors LP increased its holdings in shares of Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after purchasing an additional 1,136,245 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after purchasing an additional 1,020,243 shares during the period. Bank of America Corp DE increased its holdings in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Esperion Therapeutics by 18.6% during the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares during the period. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.